GMAB · Genmab A/S

The thesis

Genmab's own cancer drugs are becoming a second source of revenue beside its royalty on Johnson & Johnson's DARZALEX, and the shares are more likely than not to beat the S&P 500 over the next three months. Three things settle the case: the American Society of Hematology (ASH) meeting on 12 December to 15 December 2026, Genmab's R&D update on 16 December 2026, and regulatory filings ahead of the launches management expects in 2027.

The rating is Medium. The 5 November 2026 third-quarter report kept all 2026 guidance unchanged. At the Wolfe Research conference on 10 November 2026, Chief Financial Officer Anthony Pagano said Genmab expects to launch three drugs in 2027, EPKINLY in new uses, petosemtamab and Rina-S, per Investing.com's transcript. The shares fell from a $55.80 close on 9 November 2026 to $51.74 on 12 November 2026. The only company news in that period was routine: an employee warrant exercise and small sales by two board members.

The price already reflects the October Phase 3 successes. Investing.com put Genmab's market value at $34.6B on 10 November 2026, against trailing twelve-month revenue of $4.3B, and the shares are up 62.0% over three months. From here, gains depend on ASH data and filing dates. Reruns of the October headlines will not do it.

Bullish and bearish views on Genmab A/S ADS

The bull case on Genmab A/S ADS (GMAB), in brief: own-drug sales keep compounding. The bear case: revenue narrowly missed and guidance did not rise.

Bull case

• Own-drug sales keep compounding. EPKINLY/TEPKINLY global net sales were $179M in the third quarter of 2026, up from $122M a year earlier, and $491M over nine months against $333M, per Genmab's interim report filed on Form 6-K on 5 November 2026.
• The royalty stream is still growing. Nine-month 2026 revenue was $3,238M, up 22%, of which royalties were $2,699M, per the same report. Third-quarter DARZALEX royalties rose 14% to $751M.
• Profit guidance has room. Nine-month adjusted operating profit of $1,108M already exceeds the $1,065M low end of Genmab's 2026 range of $1,065–1,385M, per the 5 November 2026 report. That cushions the higher fourth-quarter spending management flagged on its call.
• Petosemtamab halved the risk of death. Genmab reported on 28 October 2026 that Phase 3 LiGeR-HN1 met both primary goals at its first interim analysis in first-line PD-L1-positive head and neck cancer. The overall survival (OS) hazard ratio was 0.50, with a 95% confidence interval of 0.37–0.67.
• Rina-S showed a large ovarian cancer benefit. Genmab's Form 6-K of 23 October 2026 reports a progression-free survival hazard ratio of 0.29 in the 584-patient RAINFOL-02 intent-to-treat group, with an OS hazard ratio of 0.43.
• Management raised Rina-S expectations. On 10 November 2026 the CFO put Rina-S peak sales above $2 billion, up from $1 billion at its April 2024 acquisition, and kept EPKINLY peak sales above $3 billion, per Investing.com.
• ASH brings more epcoritamab data. Genmab announced 22 epcoritamab abstracts on 4 November 2026. They include primary Phase 3 EPCORE DLBCL-4 results in an oral session on 14 December 2026 and first EPCORE CLL-1 results on 12 December 2026.

Bear case

• Revenue narrowly missed and guidance did not rise. Third-quarter revenue of $1,187M compared with a $1,194M estimate, Benzinga reported on 5 November 2026. Benzinga put the full-year sales consensus at $4.472B, above the $4,425M midpoint of Genmab's unchanged $4,325–4,525M range.
• The earnings beat leans on tax. Diluted earnings per share of $5.51 beat a $3.59 estimate, per Benzinga on 5 November 2026. The estimated annual effective tax rate fell to 3.4% from 18.9% on Merus-related tax benefits, and management said in the report that the rate is not indicative of future periods.
• The readouts did not lift management's targets. The CFO said on 10 November 2026 that peak-sales estimates are unchanged because they were already built on Phase 2 data, per Investing.com. He gave no number for petosemtamab and no filing date for either new drug.
• One epcoritamab trial failed in the US. Genmab and AbbVie said on 23 July 2026 that EPCORE DLBCL-1 missed statistical significance on its sole US primary endpoint, overall survival. That puts more weight on the other lymphoma trials.
• Merus left real debt. Borrowings were $4,992M at 30 September 2026 against cash of $1,860M, per the interim report, after the Merus acquisition.

Price setup

The shares closed at $51.74 on 12 November 2026. That is 13.7% below the 52-week intraday high of $59.97, set on 28 October 2026, the day of the LiGeR-HN1 readout. The close a session earlier, on 11 November 2026, was $53.87.

The 50-day moving average was $40.81 and the 200-day was $31.45 at the 12 November 2026 close, in adjusted daily closes. The shares are up 62.0% from $31.94 on 14 August 2026. The 52-week closing low was $23.85 on 2 June 2026. The gap between the price and the 50-day average shows how much of the value rests on the October readouts.

Supply news since the report is small. Genmab said on 11 November 2026 that it is issuing 164,828 new shares after employees exercised warrants, raising about DKK 369.7 million. On 12 November 2026, Genmab disclosed under the EU Market Abuse Regulation that board members Martin Schultz and Mijke Zachariasse sold 617 and 351 shares at DKK 3,540.87 each, per TipRanks.

Catalysts ahead

• 19 November 2026: Genmab presentation at the Jefferies healthcare conference. Management could give the first filing timing for Rina-S and petosemtamab, which it did not give on 10 November 2026.
• 7 December 2026: ASH late-breaking abstracts posted. Any Genmab late-breaking abstract would add data before the meeting opens.
• 12 December 2026: First EPCORE CLL-1 results for epcoritamab at ASH. It shows whether epcoritamab has a case in chronic lymphocytic leukemia, a market beyond its current lymphoma uses.
• 14 December 2026: ASH oral presentation of primary Phase 3 EPCORE DLBCL-4 results (epcoritamab plus lenalidomide). It shows whether epcoritamab can win a new lymphoma use after the EPCORE DLBCL-1 US overall survival miss in July 2026.
• 16 December 2026: Genmab 2026 R&D update and ASH data review. Filing timing for Rina-S and petosemtamab here decides whether the three 2027 launches stay on track.
• ~January 2027 (est.): Johnson & Johnson fourth-quarter report with DARZALEX net sales. DARZALEX royalties fund the launches, so it shows whether royalty growth is holding.
• ~February 2027 (est.): Genmab full-year 2026 report and 2027 outlook. It shows whether adjusted operating profit stayed within $1,065–1,385M and how much launch spending Genmab expects in 2027.
• ~March 2027 (est.): Second-line Phase 3 readout for petosemtamab in head and neck cancer. The CFO expects it in the first quarter of 2027; a second positive trial would widen petosemtamab's market.

What would change the view

A daily close below $38, beneath the 50-day moving average, which would show the market giving back the rerating that followed the October 2026 Phase 3 readouts. 2026 adjusted operating profit under $1,065M, or full LiGeR-HN1 or RAINFOL-02 data showing serious safety problems, would also break the case.

The risks this note tracks, each with what would confirm it:

• Full LiGeR-HN1 results may show smaller absolute gains than the topline hazard ratio implies. Confirmed by: a medical-meeting presentation with a modest median OS difference, a low absolute response rate in the combination arm, or higher serious adverse event rates.
• Full RAINFOL-02 results could disappoint on tolerability. Confirmed by: high rates of serious adverse events or treatment discontinuation in the full medical-meeting presentation.
• Regulatory timelines could slip past the 2027 launches management named on 10 November 2026. Confirmed by: regulators asking for more evidence on the interim LiGeR-HN1 results, or Genmab moving its stated launch timing beyond 2027 at the 16 December 2026 R&D update or later.
• Epcoritamab's expansion into new lymphoma uses could stall. Confirmed by: weak EPCORE DLBCL-4 results at ASH on 14 December 2026, following the EPCORE DLBCL-1 US overall survival miss announced on 23 July 2026.
• The second-line petosemtamab Phase 3 trial could fail. Confirmed by: the readout the CFO expects in the first quarter of 2027 missing its primary endpoint.
• Spending on launches could eat into operating profit. Confirmed by: 2026 adjusted operating profit under $1,065M in the full-year report, or 2027 guidance showing expenses rising faster than revenue.
• Slower DARZALEX growth would hit the royalty stream that makes up most of Genmab's revenue. Confirmed by: J&J reporting lower year-on-year DARZALEX net sales, or Genmab's 2026 royalties finishing below the $3,625M low end of guidance.

What it trades with

Genmab's revenue moves with DARZALEX sales reported by Johnson & Johnson, so J&J's quarterly reports move the shares. Halozyme (HALO) also earns royalties tied to the subcutaneous form of DARZALEX, so the two can react to the same J&J sales figures. EPKINLY sales are shared with AbbVie, and Kesimpta royalties come from Novartis.

Within oncology and immunology, Xencor (XNCR) and Replimune (REPL) trade on their own trial and regulatory news more than on Genmab's. The US-traded shares are American Depositary Shares tracking the Copenhagen listing, so moves in the Danish krone against the dollar also affect the US price.